Robert H Carnahan
Overview
Explore the profile of Robert H Carnahan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
4140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jamieson P, Shen X, Abu-Shmais A, Wasdin P, Janowska K, Edwards R, et al.
bioRxiv
. 2025 Feb;
PMID: 39896680
HIV-1 continues to pose a significant global health challenge, requiring ongoing research into effective prevention and treatment strategies. Understanding the B cell repertoire that can be engaged upon vaccination in...
2.
Suryadevara N, Kose N, Bangaru S, Binshtein E, Munt J, Martinez D, et al.
J Clin Invest
. 2024 Nov;
135(3).
PMID: 39589795
The function of the spike protein N terminal domain (NTD) in coronavirus (CoV) infections is poorly understood. However, some rare antibodies that target the SARS-CoV-2 NTD potently neutralize the virus....
3.
Abu-Shmais A, Guo L, Khalil A, Miller R, Janke A, Vukovich M, et al.
bioRxiv
. 2024 Nov;
PMID: 39554078
Human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are frequent drivers of morbidity and mortality in susceptible populations, most often infantile, older adults, and immunocompromised. The primary target of...
4.
Nkolola J, Hope D, Guan R, Colarusso A, Aid M, Weiss D, et al.
J Virol
. 2024 Nov;
98(12):e0142924.
PMID: 39545728
Zika virus (ZIKV) is a mosquito-borne flavivirus that caused a global pandemic in 2016-2017 with continued ongoing transmission at low levels in several countries. In the absence of an approved...
5.
Cabel C, Guzman B, Alizadeh E, Li S, Holberg C, Wichaidit C, et al.
bioRxiv
. 2024 Oct;
PMID: 39416139
The sudden rise of the SARS-CoV-2 virus and the delay in the development of effective therapeutics to mitigate it made evident a need for ways to screen for compounds that...
6.
Johnson N, Wall S, Kramer K, Holt C, Periasamy S, Richardson S, et al.
Structure
. 2024 Sep;
32(11):1893-1909.e11.
PMID: 39326419
The continued emergence of deadly human coronaviruses from animal reservoirs highlights the need for pan-coronavirus interventions for effective pandemic preparedness. Here, using linking B cell receptor to antigen specificity through...
7.
Ilinykh P, Huang K, Gunn B, Kuzmina N, Kedarinath K, Jurado-Cobena E, et al.
Commun Biol
. 2024 Jul;
7(1):921.
PMID: 39085489
No abstract available.
8.
Ilinykh P, Huang K, Gunn B, Kuzmina N, Kedarinath K, Jurado-Cobena E, et al.
Commun Biol
. 2024 Jul;
7(1):871.
PMID: 39020082
Antibodies to Ebola virus glycoprotein (EBOV GP) represent an important correlate of the vaccine efficiency and infection survival. Both neutralization and some of the Fc-mediated effects are known to contribute...
9.
Suryadevara N, Otrelo-Cardoso A, Kose N, Hu Y, Binshtein E, Wolters R, et al.
Nat Microbiol
. 2024 Jun;
9(8):2128-2143.
PMID: 38858594
Human parainfluenza virus type 3 (hPIV3) is a respiratory pathogen that can cause severe disease in older people and infants. Currently, vaccines against hPIV3 are in clinical trials but none...
10.
Desautels T, Arrildt K, Zemla A, Lau E, Zhu F, Ricci D, et al.
Nature
. 2024 May;
629(8013):878-885.
PMID: 38720086
The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs and revealed how quickly viral escape can curtail effective options. When the SARS-CoV-2 Omicron variant emerged in...